• Home
• About us
• Contact

• News
• People
• Products
• Deals
• Organisations

• Twitter
• Newsletter

Advertisement

Organisation › Details

CRISPR Therapeutics AG (Nasdaq: CRSP)

CRISPR Therapeutics is a leading gene-editing company focused on the development of transformative gene-based medicines for serious diseases using its proprietary CRISPR/Cas9 gene-editing platform. CRISPR/Cas9 is a revolutionary technology that allows for precise, directed changes to genomic DNA. The Company’s multi-disciplinary team of world-class researchers and drug developers is working to translate this technology into breakthrough human therapeutics in a number of serious diseases. Additionally, CRISPR Therapeutics has established strategic collaborations with Bayer AG and Vertex Pharmaceuticals to develop CRISPR-based therapeutics in diseases with high unmet need. The foundational CRISPR/Cas9 patent estate for human therapeutic use was licensed from the Company’s scientific founder Emmanuelle Charpentier, Ph.D., who co-invented the application of CRISPR/Cas9 for gene editing. CRISPR Therapeutics is headquartered in Basel, Switzerland with its R&D operations based in Cambridge, Massachusetts. *

 

	Start	2013-01-01 established
	Group	CRISPR Therapeutics (Group)
	Industry	CRISPR gene editing technology
	Person	Kulkarni, Samarth (Sam) (CRISPR Therapeutics 201712– promoted CEO before CBO)
	Person 2	Foy, Shaun P. (CRISPR Therapeutics 201404 CFO + Co-Founder + ERS Genomics CEO + Co-Founder before Nomura Phase4)
	Region	Basel BS
	Country	Switzerland
	Street	36 Aeschenvorstadt
	City	4051 Basel BS
		Address record changed: 2020-12-02
Basic data	Employees	n. a.
	Currency	USD
	Annual sales	289,590,000 (revenue, collaboration, consolidated (2019) 2019-12-31)
	Profit	66,858,000 (2019-12-31)
	Cash	943,800,000 (2019-12-31)
		* Document for �About Section�:
		Record changed: 2023-03-06

Advertisement

More documents for CRISPR Therapeutics (Group)

• [1] CRISPR Therapeutics AG. (2/27/23). "Press Release: CRISPR Therapeutics to Participate in the 43rd Annual Cowen Health Care Conference". Zug & Boston, MA....
• [2] CRISPR Therapeutics AG. (2/21/23). "Press Release: CRISPR Therapeutics Provides Business Update and Reports Fourth Quarter and Full Year 2022 Financial Results". Zug & Boston, MA....
• [3] CRISPR Therapeutics AG. (12/19/22). "Press Release: CRISPR Therapeutics Announces the Appointment of Alex Harding, M.D., M.B.A., as Head of Business Development". Zug & Boston, MA....
• [4] CRISPR Therapeutics AG. (8/31/22). "Press Release: CRISPR Therapeutics to Participate in Upcoming Investor Conferences". Zug & Cambridge, MA....
• [5] CRISPR Therapeutics AG. (10/14/21). "Press Release: CRISPR Therapeutics Announces Transition of Chief Financial Officer". Zug & Cambridge, MA....
• [6] CRISPR Therapeutics AG. (5/6/21). "Press Release: CRISPR Therapeutics and Nkarta Announce Global Collaboration to Develop Gene-Edited Cell Therapies for Cancer". Zug, Cambridge, MA & South San Francisco, CA....
• [7] CRISPR Therapeutics AG. (2/1/21). "Press Release: CRISPR Therapeutics Announces the Appointment of Philippe Drouet as Chief Commercial Officer". Zug & Cambridge, MA....
• [8] CRISPR Therapeutics AG. (10/28/20). "Press Release: CRISPR Therapeutics Provides Business Update and Reports Third Quarter 2020 Financial Results". Zug & Cambridge, MA....
• [9] CRISPR Therapeutics AG. (6/30/20). "Press Release: CRISPR Therapeutics Announces Pricing of Public Offering of Common Shares". Zug & Cambridge, MA....
• [10] CRISPR Therapeutics AG. (6/29/20). "Press Release: CRISPR Therapeutics Announces Proposed Offering of Common Shares". Zug & Cambridge, MA....

To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to info@iito.de and simply fill the subject line with the word »LSE Newsletter«

Find more infos about advertising at [iito] web portals in our media flyer [iito] in a Nutshell [PDF file]

Advertisement

» top

» Imprint  |  » Data Privacy  |  » Contact  |  The use of this website requires to accept the » Disclaimer!   |  A project of [iito] Business Intelligence © 2002-2023. Made in Germany.